Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies

Bioorg Med Chem Lett. 2005 Mar 1;15(5):1509-13. doi: 10.1016/j.bmcl.2004.12.068.

Abstract

A screening assay program on HIV-protease was carried out on more than fifty commercially available N-protected amino acids and has revealed that those with a long side chain such as lysine, ornithine and arginine exhibited significant inhibition of HIV protease enzyme. The presence of an Fmoc group was found to be essential to obtain micromolar inhibitors and the addition of an alkyl group at the Nalpha-position resulted in the discovery of the lead compound 11 displaying a 5 nM inhibition constant. Although this new inhibitor series is not categorized among those mimicking the substrate with a non-hydrolyzable transition-state isoster, it was found very specific to inhibit HIV protease enzyme in comparison to the mammalian aspartyl proteases pepsin, renin and cathepsin. Furthermore, these inhibitors did not show any cytotoxicity at a concentration below 75 microM.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Cathepsins / antagonists & inhibitors
  • Drug Evaluation, Preclinical
  • HIV Protease / drug effects*
  • HIV Protease Inhibitors / chemical synthesis
  • HIV Protease Inhibitors / chemistry*
  • HIV Protease Inhibitors / pharmacology*
  • Humans
  • Lysine / analogs & derivatives*
  • Lysine / chemical synthesis
  • Lysine / pharmacology*
  • Molecular Structure
  • Pepsin A / antagonists & inhibitors
  • Renin / antagonists & inhibitors
  • Structure-Activity Relationship

Substances

  • HIV Protease Inhibitors
  • Cathepsins
  • HIV Protease
  • Pepsin A
  • Renin
  • Lysine